A group comprised of CBD industry stakeholders recently submitted a study to Congress indicating potential upper oral intake limits for safe cannabidiol usage by consumers.
Early this year, the USA’s Food and Drug Administration (FDA) passed the buck on implementing cannabidiol regulations to Congress. This was followed by a Request for Information from Congress on the concerns FDA has raised with regard to CBD product regulation.
ONE HEMP’s aim is to see regulatory standards implemented by Congress and the FDA that treat CBD products as dietary supplements, and to serve as a leading scientific resource to policymakers to ensure consumer safety and consistency. Among ONE HEMP’s member organisations is Charlotte’s Web, a hemp extract wellness product company that announced its founding membership this week.
“Today, the uncertainty faced by thousands of companies and American farmers coupled with the confusion for millions of CBD consumers is unacceptable,” said Jared Stanley, Co-Founder and Chief Operating Officer of Charlotte’s Web. “It is time for Congress to clarify the FDA’s mandate and definitively regulate CBD products as dietary supplements once and for all.”
Chief Scientific Officer at Charlotte’s Web, Dr. Marcel Bonn-Miller Ph.D., was recently part of a research team delving into oral intake limits for safe CBD usage. After reviewing publicly available human and animal safety studies of CBD, a recommended upper intake limit of 70mg/day was determined for healthy adults and a limit of up to 160mg/day was identified for healthy adults excluding those trying to conceive, or currently pregnant or lactating.
It’s important to note “healthy adults” were defined in this study as those without medical conditions or taking medications. The latter is particularly important as cannabinoids such as cannabidiol have the potential to interact with some medicines, impacting their effectiveness.
“This study will help to inform legislators and regulators as they determine manufacturing and labeling requirements for supplement products containing CBD,” said Dr. Bonn-Miller. ” This research is also aligned with ONE HEMP’s recommendations for accurate product labeling and, ultimately, holding CBD companies accountable for manufacturing and selling quality and safe products.”
Study lead Dr. Rayetta G. Henderson Ph.D., Senior Managing Scientist at ToxStrategies LLC, said the study’s suggested Upper Intake Limits closely corresponded with recommendations from several leading regulatory bodies outside the USA. Additionally:
“they provide a sufficient margin of safety for potential adverse effects and help to establish a safe framework for CBD consumption.”